Surgery Partners (SGRY) Q2 2026 earnings review
Acuity Masks Stagnant Volumes as Divestiture Transforms Profile
Surgery Partners delivered a mixed Q2 where top-line growth masked underlying volume and margin weaknesses. While same-facility revenue grew 5.0%, this was entirely driven by rate (+4.8%) as case volumes severely decelerated to just +0.3%. Without volume leverage, margins suffered a reversing trend: Adjusted EBITDA fell 3% YoY to $125.2M, and the net loss widened to $15.0M. The defining story, however, is the pending Idaho Falls divestiture. This portfolio optimization move will strip out ~$765M in annual revenue but will dramatically de-risk the payor mix by cutting Medicaid exposure by 50% and generate much-needed capital to address the company's 4.4x net leverage.
🐂 Bull Case
The pending divestiture is a masterstroke in portfolio optimization. It removes capital-intensive, non-core operations, slashes Medicaid exposure to under 2% of proforma revenue, and will likely provide significant proceeds to rapidly deleverage the balance sheet.
The 4.8% jump in same-facility revenue per case proves the high-acuity (orthopedics/robotics) migration strategy is working, insulating the top line even when overall patient traffic is flat.
🐻 Bear Case
A 0.3% same-facility case growth rate falls significantly short of the company's long-term 2-3% algorithm, continuing a multi-quarter deceleration that limits operating leverage.
Adjusted EBITDA margins compressed by 90 bps to 14.7%. Combined with heavy interest expenses ($69.8M in Q2), operating cash flow dropped 27% YoY to $59.3M, leaving less capital for aggressive M&A.
⚖️ Verdict: ⚪
Neutral. The operational weakness—flat volumes and margin compression—is a glaring concern for a roll-up story. However, the decisive Idaho Falls divestiture offers a credible 'addition by subtraction' reset that should yield a higher-quality, lower-leverage core business.
Key Themes
Case Volume Stagnation
Decelerating. Same-facility case growth cratered to 0.3% in Q2, down from 0.6% in Q1 and 3.4% a year ago. Without patient traffic growth, the company is entirely reliant on price/acuity increases. If the migration of high-acuity cases to ASCs slows, the current growth algorithm will break.
The Idaho Falls Divestiture Transformation
This is the most significant portfolio shift in recent history. The divestiture removes a massive, atypical asset ($765M annualized revenue). Crucially, it eliminates obstetrics, neonatology, inpatient pediatrics, and heavy emergency department volumes. Post-sale, the company's Medicaid payor mix will plummet by 50% to roughly 2% of total revenue, leaving a purer, higher-margin ASC footprint.
High-Acuity Shift Sustains Top Line
Accelerating. While case volumes stalled, revenue per case surged 4.8% to $4,898. This confirms that the shift toward complex, high-reimbursement procedures (like total joints and MSK) is effectively protecting same-facility revenue growth (5.0%). The ongoing recruitment of ~190 physicians in Q2 continues to fuel this acuity mix shift.
Margin Compression Resurfaces
Reversing. After showing cost-control promise in prior quarters, margins took a hit. Adjusted EBITDA dropped 3% YoY, and margin compressed from 15.6% to 14.7%. Salaries and benefits jumped to 29.8% of revenue (up from 28.5% in 25Q2). The lack of volume leverage means fixed costs are eating into profitability.
Debt Burden Constraining Cash Flow
Stable but heavy. Net leverage sits at 4.4x. The company generated $102.1M in operating income in Q2, but $69.8M of that was immediately consumed by net interest expense. This dynamic caused operating cash flow to fall 27% YoY to $59.3M, increasing the reliance on divestiture proceeds to fund future growth.
Other KPIs
Decelerating. Down significantly from $81.3M in the prior year quarter. Year-to-date operating cash flow sits at $71.0M, trailing the $87.3M generated in the first half of 2025. This contraction highlights the pressure of rising operational costs and elevated interest burdens.
Reversing. A sharp deterioration from the $(2.5)M loss in 25Q2. The widening loss is largely attributable to higher salaries, supplies, and a steady drumbeat of transaction/integration costs ($18.4M), overshadowing the modest 2.7% top-line growth.
Guidance
Stable. The company reaffirmed its full-year guidance, which represents status quo operations (excluding the pending Idaho Falls divestiture execution). At the midpoint, this implies a modest ~2.7% YoY growth rate compared to FY25's $3.31B.
Stable. Reaffirmed on a status quo basis. However, management provided a critical 'Proforma' look: stripping out the $116M annualized EBITDA from the Idaho Falls market, the base business is guided to generate $414M+. The company projects this proforma base to achieve 4.2%+ organic growth.
Management guided Q3 revenue to 25.0%-25.5% of the annual midpoint, and EBITDA to 25.75%-26.25% of the annual target. This implies roughly flat sequential revenue from Q2, but expects a margin step-up into the third quarter.
Key Questions
Idaho Falls Proceeds & Deleveraging
Assuming regulatory and partner approvals clear for the Idaho Falls divestiture, what is the expected cash yield to SGRY, and how rapidly do you expect net leverage to drop below the 4.0x threshold?
Addressing Volume Stagnation
Same-facility case growth was nearly flat at 0.3% this quarter. While acuity is driving revenue, how are you addressing the lack of underlying patient traffic, and when do you expect volume growth to return to the historical 2-3% algorithm?
Margin Trajectory Post-Divestiture
The proforma guidance strips out $116M in EBITDA and massive Medicaid exposure. With this structural change, what is the expected normalized Adjusted EBITDA margin profile for the remaining core business in 2027?